FDA 483 - Cipla Limited - November 13, 2024

An FDA inspection conducted at CIPLA Limited's Active Pharmaceutical Ingredient (API) manufacturing facility in Bengaluru, India, from November 7-13, 2024, revealed eight significant observations. The findings indicate critical deficiencies across various systems, primarily concerning Good Manufacturing Practices (GMP) and ICH Q7 guidelines.Key issues identified include inadequate controls for equipment maintenance, cleaning, and qualification, with visible residues and contamination found on supposedly cleaned equipment. The cleaning validation program was deemed insufficient, and preventive maintenance for critical equipment was overdue. The production system showed failures in documenting and monitoring critical process parameters, lack of operator presence during automated steps, and deficient environmental monitoring.The Quality Unit demonstrated a failure to establish site-specific procedures, integrate ICH Q7 into cGMP training, effectively manage change controls, and conduct necessary transportation studies for temperature-sensitive APIs. Investigations into primary packaging complaints were inadequate, lacking comprehensive root cause analysis and corrective actions. Additionally, packaging material acceptance criteria were not updated following configuration changes, and laboratory controls suffered from overdue instrument maintenance and delayed stability testing.CIPLA Limited is required to provide a formal response addressing these observations and outlining corrective and preventive actions to ensure compliance with regulatory standards for API manufacturing.